<?xml version='1.0' encoding='utf-8'?>
<document id="8912496"><sentence text="Acute phenytoin toxicity followed by seizure breakthrough from a ticlopidine-phenytoin interaction."><entity charOffset="6-15" id="DDI-PubMed.8912496.s1.e0" text="phenytoin" /><entity charOffset="65-76" id="DDI-PubMed.8912496.s1.e1" text="ticlopidine" /><entity charOffset="77-86" id="DDI-PubMed.8912496.s1.e2" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.8912496.s1.e0" e2="DDI-PubMed.8912496.s1.e0" /><pair ddi="false" e1="DDI-PubMed.8912496.s1.e0" e2="DDI-PubMed.8912496.s1.e1" /><pair ddi="false" e1="DDI-PubMed.8912496.s1.e0" e2="DDI-PubMed.8912496.s1.e2" /><pair ddi="false" e1="DDI-PubMed.8912496.s1.e1" e2="DDI-PubMed.8912496.s1.e1" /><pair ddi="false" e1="DDI-PubMed.8912496.s1.e1" e2="DDI-PubMed.8912496.s1.e2" /></sentence><sentence text="To review a case of a drug-drug interaction between phenytoin sodium and ticlopidine hydrochloride that resulted in acute phenytoin toxicity and permanent memory loss"><entity charOffset="52-68" id="DDI-PubMed.8912496.s2.e0" text="phenytoin sodium" /><entity charOffset="73-98" id="DDI-PubMed.8912496.s2.e1" text="ticlopidine hydrochloride" /><entity charOffset="122-131" id="DDI-PubMed.8912496.s2.e2" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.8912496.s2.e0" e2="DDI-PubMed.8912496.s2.e0" /><pair ddi="false" e1="DDI-PubMed.8912496.s2.e0" e2="DDI-PubMed.8912496.s2.e1" /><pair ddi="false" e1="DDI-PubMed.8912496.s2.e0" e2="DDI-PubMed.8912496.s2.e2" /><pair ddi="false" e1="DDI-PubMed.8912496.s2.e1" e2="DDI-PubMed.8912496.s2.e1" /><pair ddi="false" e1="DDI-PubMed.8912496.s2.e1" e2="DDI-PubMed.8912496.s2.e2" /></sentence><sentence text="" /><sentence text="A 63-year-old man who was maintained with a stable dose of phenytoin for treatment of seizures began treatment with ticlopidine following percutaneous transluminal angioplasty and stent placement"><entity charOffset="59-68" id="DDI-PubMed.8912496.s4.e0" text="phenytoin" /><entity charOffset="116-127" id="DDI-PubMed.8912496.s4.e1" text="ticlopidine" /><pair ddi="false" e1="DDI-PubMed.8912496.s4.e0" e2="DDI-PubMed.8912496.s4.e0" /><pair ddi="false" e1="DDI-PubMed.8912496.s4.e0" e2="DDI-PubMed.8912496.s4.e1" /></sentence><sentence text=" Within 3 weeks of beginning treatment with ticlopidine, he experienced acute clinical toxic effects of phenytoin with a maximum measured phenytoin concentration of 162"><entity charOffset="44-55" id="DDI-PubMed.8912496.s5.e0" text="ticlopidine" /><entity charOffset="104-113" id="DDI-PubMed.8912496.s5.e1" text="phenytoin" /><entity charOffset="138-147" id="DDI-PubMed.8912496.s5.e2" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.8912496.s5.e0" e2="DDI-PubMed.8912496.s5.e0" /><pair ddi="false" e1="DDI-PubMed.8912496.s5.e0" e2="DDI-PubMed.8912496.s5.e1" /><pair ddi="false" e1="DDI-PubMed.8912496.s5.e0" e2="DDI-PubMed.8912496.s5.e2" /><pair ddi="false" e1="DDI-PubMed.8912496.s5.e1" e2="DDI-PubMed.8912496.s5.e1" /><pair ddi="false" e1="DDI-PubMed.8912496.s5.e1" e2="DDI-PubMed.8912496.s5.e2" /></sentence><sentence text="4 micromol/L" /><sentence text=" Phenytoin concentration decreased to 36 micromol/L after discontinuing treatment with ticlopidine and reducing the phenytoin dose"><entity charOffset="1-10" id="DDI-PubMed.8912496.s7.e0" text="Phenytoin" /><entity charOffset="87-98" id="DDI-PubMed.8912496.s7.e1" text="ticlopidine" /><entity charOffset="116-125" id="DDI-PubMed.8912496.s7.e2" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.8912496.s7.e0" e2="DDI-PubMed.8912496.s7.e0" /><pair ddi="false" e1="DDI-PubMed.8912496.s7.e0" e2="DDI-PubMed.8912496.s7.e1" /><pair ddi="false" e1="DDI-PubMed.8912496.s7.e0" e2="DDI-PubMed.8912496.s7.e2" /><pair ddi="false" e1="DDI-PubMed.8912496.s7.e1" e2="DDI-PubMed.8912496.s7.e1" /><pair ddi="false" e1="DDI-PubMed.8912496.s7.e1" e2="DDI-PubMed.8912496.s7.e2" /></sentence><sentence text=" Subsequently, the patient developed probable complex partial status epilepticus" /><sentence text="" /><sentence text="Ticlopidine is a metabolic inhibitor of several drugs"><entity charOffset="0-11" id="DDI-PubMed.8912496.s10.e0" text="Ticlopidine" /></sentence><sentence text=" Because of the potential for acute and permanent adverse effects from a drug-drug interaction, phenytoin concentrations should be carefully monitored when beginning or ending ticlopidine therapy"><entity charOffset="96-105" id="DDI-PubMed.8912496.s11.e0" text="phenytoin" /><entity charOffset="176-187" id="DDI-PubMed.8912496.s11.e1" text="ticlopidine" /><pair ddi="false" e1="DDI-PubMed.8912496.s11.e0" e2="DDI-PubMed.8912496.s11.e0" /><pair ddi="false" e1="DDI-PubMed.8912496.s11.e0" e2="DDI-PubMed.8912496.s11.e1" /></sentence><sentence text="" /></document>